Aurealis Therapeutics Raises $10 Million Series A To Drive Multi-Factor Bacterial Vectors in Chronic Wounds and Oncology
Kuopio, Finland – March 30th 2023. Aurealis Therapeutics, a synthetic biology company
Norra Savolax Jasper Zheng Juha Yrj Lactococcus Cremoris Huahai Pharmaceuticals Finnish Industry Investment Ltd
Source: einnews.com